JP2023530500A5 - - Google Patents
Info
- Publication number
- JP2023530500A5 JP2023530500A5 JP2022578719A JP2022578719A JP2023530500A5 JP 2023530500 A5 JP2023530500 A5 JP 2023530500A5 JP 2022578719 A JP2022578719 A JP 2022578719A JP 2022578719 A JP2022578719 A JP 2022578719A JP 2023530500 A5 JP2023530500 A5 JP 2023530500A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- cbd
- caffeine
- reduces
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2009321.7A GB202009321D0 (en) | 2020-06-18 | 2020-06-18 | Use of cannabinoids in the treatment of epilepsy |
| GB2009321.7 | 2020-06-18 | ||
| PCT/GB2021/051520 WO2021255446A1 (en) | 2020-06-18 | 2021-06-16 | Use of cannabidiol in the treatment of epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530500A JP2023530500A (ja) | 2023-07-18 |
| JP2023530500A5 true JP2023530500A5 (enExample) | 2024-06-25 |
Family
ID=71838306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578719A Pending JP2023530500A (ja) | 2020-06-18 | 2021-06-16 | てんかんの治療におけるカンナビジオールの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230225986A1 (enExample) |
| EP (1) | EP4167980B1 (enExample) |
| JP (1) | JP2023530500A (enExample) |
| KR (1) | KR20230026337A (enExample) |
| CN (1) | CN115916168A (enExample) |
| AU (1) | AU2021291128A1 (enExample) |
| CA (1) | CA3181694A1 (enExample) |
| GB (2) | GB202009321D0 (enExample) |
| MX (1) | MX2022016038A (enExample) |
| TW (1) | TW202214217A (enExample) |
| WO (1) | WO2021255446A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2025019898A1 (en) * | 2023-07-25 | 2025-01-30 | Algorae Pharmaceuticals Ltd | Compositions and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11793769B2 (en) * | 2014-08-25 | 2023-10-24 | Jai Shankar Sukul | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US20180360771A1 (en) * | 2017-06-14 | 2018-12-20 | Yury Leon Shmerlis | Cannabidiol chewing gum |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CN109985042A (zh) * | 2017-12-29 | 2019-07-09 | 汉义生物科技（北京）有限公司 | 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用 |
| US20200172841A1 (en) * | 2018-12-04 | 2020-06-04 | Donald F. Wilkes | Alcohol-free wine beverage |
-
2020
- 2020-06-18 GB GBGB2009321.7A patent/GB202009321D0/en not_active Ceased
-
2021
- 2021-06-16 KR KR1020227044124A patent/KR20230026337A/ko active Pending
- 2021-06-16 CA CA3181694A patent/CA3181694A1/en active Pending
- 2021-06-16 CN CN202180042463.2A patent/CN115916168A/zh active Pending
- 2021-06-16 WO PCT/GB2021/051520 patent/WO2021255446A1/en not_active Ceased
- 2021-06-16 US US18/002,437 patent/US20230225986A1/en active Pending
- 2021-06-16 JP JP2022578719A patent/JP2023530500A/ja active Pending
- 2021-06-16 AU AU2021291128A patent/AU2021291128A1/en active Pending
- 2021-06-16 EP EP21736654.1A patent/EP4167980B1/en active Active
- 2021-06-16 MX MX2022016038A patent/MX2022016038A/es unknown
- 2021-06-17 GB GB2108690.5A patent/GB2598187A/en not_active Withdrawn
- 2021-06-17 TW TW110122055A patent/TW202214217A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4061344T3 (fi) | 6-hydroksikannabidioli käytettäväksi lääkkeenä | |
| JP2023168448A5 (enExample) | ||
| JP7391019B2 (ja) | レノックス・ガストー症候群に関連した発作の治療におけるカンナビノイドの使用 | |
| EP3763361B1 (en) | Cannabidivarin (cbdv) for use in the treatment of epilepsy | |
| CA2582289C (en) | Inhibition of tumour cell migration | |
| JP2023503303A5 (enExample) | ||
| CN111542320A (zh) | 大麻素在癫痫治疗中的用途 | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2014533680A5 (enExample) | ||
| HK1198619A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| MX2009004908A (es) | Compuestos quimicos. | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2014145931A (ru) | Композиция для лечения нарушений метаболизма | |
| Fernandes | Neuroinflammation and Mitochondrial Dysfunction in the Pathogenesis of Alzheimer? s Disease: Modulation by Coriolus Versicolor (Yun-Zhi) Nutritional Mushroom | |
| WO2011104900A1 (ja) | 抗真菌剤 | |
| Samad | Rice bran oil prevents neuroleptic-induced extrapyramidal symptoms in rats: Possible antioxidant mechanisms | |
| WO2008152068A3 (en) | [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases | |
| KR20200065012A (ko) | 글리신 뇌병증 치료를 위한 벤조에이트 함유 조성물의 사용 | |
| ATE418540T1 (de) | Galloylpeptide | |
| JP2013129627A (ja) | フロロタンニン類の簡易な調製方法とその利用 | |
| CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
| EP3280407B1 (en) | Use of isothiocyanate derivatives as modulators of peripheral and neuropathic pain | |
| JP7556350B2 (ja) | がん細胞増殖抑制剤及びがん細胞増殖抑制用組成物 |